Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.47 USD +2.80% Intraday chart for Perspective Therapeutics, Inc. +3.52% +265.67%
Apr. 09 B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating MT
Apr. 01 Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Perspective Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K
PU
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating
MT
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
GL
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating
MT
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
AQ
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Markets Steady -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study
MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
GL
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
CI
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
GL
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors
CI
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
GL
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
AQ
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.